Abstract
Dysphagia or difficulty in swallowing is a problem in all age groups but more so in the elderly. It can be either primarily oropharyngeal or esophageal in origin. Patients with oropharyngeal dysphagia can present with symptoms of coughing or choking with swallowing, food sticking in throat, drooling, nasal regurgitation, weight loss, and episodes of recurrent pneumonia. Esophageal dysphagia can lead to sensation of food sticking in chest, oral or pharyngeal regurgitation, food sticking in throat, drooling, and weight loss [1]. Elderly population with dysphagia has a higher risk of malnutrition, nonhealing wounds, bed sores, and aspiration pneumonia. This is especially common in patients with dysphagia due to neurological diseases, neurodegenerative diseases, or brain injury. A study using Subjective Global Assessment to assess nutritional status found that 16 % of patients with dysphagia related to brain disorders had concomitant malnutrition whereas 22 % of patients with neurodegenerative diseases had associated malnutrition [2].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Castell DO, Donner MW. Evaluation of dysphagia: a careful history is crucial. Dysphagia. 1987;2:65–71.
Palmer JB, et al. Evaluation and treatment of swallowing impairments. Am Fam Physician. 2000;61(8):2453–62.
Crary MA, Groher ME. Introduction to adult swallowing disorders. Philadelphia: Butterworth Heinemann; 2003.
DeVries DR, et al. Gastroesophageal reflux disease, relation with hiatal hernia, body mass index, esophageal acid exposure. Am J Gastroenterol. 2008;103:1349–54.
Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index at risk patients for Barett’s esophagus. Gastroenterology. 2007;133:34–41.
Hirshowitz BI, Simmons J, et al. Risk factors for esophagitis in extreme acid hyper secretion with or without Zollinger-Ellison syndrome. Clin Gastroenterol Hepatol. 2004;2:220–9.
Dellon ES, Shaeen NJ. Does screening for Barrett’s esophagus and adenocarcinoma prolong survival? J Clin Oncol. 2005;23:4478–82.
Vakil N, Van Zarter SV, Kahriks P, et al. The Montreal Definition and classification of GERD: a global evidence based consensus. Am J Gastroenterol. 2006;101:1900–2000.
Armstrong D, Marshall JK, Chiba N, et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults. Update 2004. Can J Gastroenterol. 2004;19:15–35.
Kahrilas PJ, Shaeen NJ, Vaezi M. Management of gastroesophageal reflux disease. Gastroenterology. 2008;135:1392–413.
Khan M, Santana J, Donellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux esophagitis. Cochrane Database Syst Rev. 2007;2:CD003244.
Shaeen N, Ransohoff DF. Gastroesophageal reflux, Barrett’s esophagus and esophageal cancer: scientific review. JAMA. 2002;287:1972–81.
Sethumadavan S, Ramanathan J, Rammouni R, et al. An overview. Am J Gastroenterol. 2001;96:226.
Baehr PH, McDonald GB. Esophageal infections: risk factors, presentations, diagnosis and treatment. Gastroenterology. 1994;106:509.
Mc Cord GS, Clouse RE. Pill-induced esophageal structures. Clinical features and risk factors for development. Am J Med. 1990;88:512.
Bova JG, Dutton NE, Godstein HM, et al. Medication -induced esophagitis: diagnosis by double-contrast esophagography. Am J Roentgenol. 1987;148:731.
Edwards P, Turner J, Gold J, et al. Esophageal ulceration induced by zidovudine. Ann Intern Med. 1990;91:27.
Indorff A, Pergram PS. Esophageal ulceration related to zalcitabine. Ann Intern Med. 1992;117:133.
De Groen PC, Lubbe CF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996;335:1016.
Macebo G, Azevedo F, Riberio T. Ulcerative esophagitis caused by etidronate. Gastrointest Endosc. 2001;53:250.
Licking EG, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognised problem in gastrointestinal tolerability. Osteoporos Int. 1994;4:320.
Kikendall JW. Pill- induced esophageal injury. In: Castell DO, Richter JE, editors. The esophagus. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 572.
Schubert MM, Peterson DE, Lloid ME. Oral complications in hematopoietic cell transplantation. 2nd ed. Cambridge: Blakwell Science; 1999. p. 751.
Hey H, Jorgensen F, Sirensen K, et al. Esophageal transit of six commonly used tablets & capsules. BMJ. 1982;285:1717.
Pandolfino JE, Kwiatek MA, Nealis T, et al. Achalasia: a new clinically relevant classification by high resolution Manometry. Gastroenterology. 2008;135:1526–33.
Csendes A, Smok G, Braghetto I, et al. Gastroesophageal sphincter pressure and histologic changes in distal esophagus in patients with achalasia. Dig Dis Sci. 1985;30:941–5.
Boeckxstaens GE. Achalasia: virus- induced euthanasia of neurons. Am J Gastroenterol. 2008;103:1610–2.
Facco M, Brun P, Baesso I, et al. T Cells in my enteric plexus of achalasia patients show a skewed TCR repertoire and react to HSV-1 antigens. Am J Gastroenterol. 2008;103:1598–609.
Clark SB, Rice TW, Tubbs RR, et al. The nature of myenteric infiltrate in achalasia. An immunohistochemical analysis. Am J Surg Pathol. 2000;24:1153–8.
Qualman SJ, Haupt HM, Yang P, Hamilton SR. Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Gastroenterology. 1986;90:924–9.
Vantrappen G, Hellemans J. Treatment of achalasia and related motor disorders. Gastroenterology. 1980;79:144–54.
Drewes AM, Gregersen H. Multimodal pain stimulation of gastrointestinal tract. World J Gastroenterol. 2006;12:2477–86.
Richter JE. Surgery or pneumatic dilatation for achalasia. A head to head comparison. Gastroenterology. 1989;97:1340–1.
Bortoletti M, Labo G. Clinical and manometric effects of patients in with esophageal achalasia. Gastroenterology. 1981;80:39–44.
Gelfond M, Rozen P, Gilat T. Isosorbide dinitrate and nifedipine treatment of achalasia. A clinical and manometric and radionuclide evaluation. Gastroenterology. 1982;83:963–9.
Traube M, Hongo M, Magyar L, McCallum RW. Effects of nifedipine in achalasia and in patients with high amplitude peristaltic esophageal contractions. JAMA. 1984;252:1733–6.
Bortolotti M, Mari C, Lopilato C, et al. Effects of sildenafil on esophageal motility of patients with idiopathic achalasia. Gastroenterology. 2000;118:253–7.
Pasricha PJ, Ravich WJ, Hendrix TR, et al. Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med. 1995;332:774–8.
Rothenberg ME. Eosinophilic gastrointestinal disorders. J Allergy Clin Immunol. 2004;113:11–28.
Lucendo AJ, Arias Á, González-Cervera J et al: Empiric 6-food elimination diet induced and maintained prolonged remission in patients with adult eosinophilic esophagitis: a prospective study on the food cause of the disease. J Allergy Clin Immunol. 2013;131(3):797–804. doi:10.1016/j.jaci.2012.12.664. Epub 2013 Jan 31.
Ngo P, Furuta G, Antonioli D, Fox V. Eosinophils in the esophagus- peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. Am J Gastroenterol. 2006;101:1666–70.
Spechler SJ, Genta RM, Souza RF. Thoughts on complex relationship between GERD and eosinophilic esophagitis. Am J Gastroenterol. 2007;102:1301–6.
Furuta GT, Liacouras CA, Collin MH, et al. Eosinophilic Esophagitis in children and adults: a systematic review and consensus recommendation for diagnosis and treatment. Gastroenterology. 2007;133:1342–63.
Arora AS, Perrault J, Smyrk TC. Topical corticosteroid treatment of dysphagia due to eosinophilic esophagitis in adults. Mayo Clin Proc. 2003;63:3–12.
Stein MK, Collins MH, Villanuaeva JM, et al. Anti-IL-5 therapy for eosinophilic esophagitis. J Allergy Clin Immunol. 2006;118:1312–9.
Macht M, Wimbish T, Benson AB, Burnham EL, et al. Post extubation failure is persistent and associated with poor outcomes in survivors of critical illness. Crit Care. 2011;15:R231.
Macht M, Wimbish T, Moss M. ICU-acquired swallowing disorders. Crit Care Med. 2013;41(10):2396–405.
Rose S, Young MA, Reynolds JC. Gastrointestinal manifestations of scleroderma. Gastroenterol Clin North Am. 1998;27:563–94.
Lapadula G, Muolo P, Semeraro F, et al. Esophageal motility disorders in rheumatic diseases: a review of 150 patients. Clin Exp Rheumatol. 1994;12:515–21.
Gareth JM, Winkleman RK, Schlegel JF, Code CF. Esophageal deterioration in scleroderma. Mayo Clin Proc. 1971;46:92–6.
Bassotti G, Battaglia E, Debernandi V, et al. Esophageal dysfunction in scleroderma: relationship with disease subsets. Arthritis Rheum. 1997;49:2252–9.
Ebert EC. Esophageal disease in scleroderma. J Clin Gastroenterol. 2006;40:769–75.
Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum. 1994;37:1265–82.
Janssen M, Dijkmans BAC, Lamers CBHW. Upper gastrointestinal involvement in rheumatoid arthritis patients: intrinsic or extrinsic pathogenesis? Scand J Gastroenterol. 1990;25 Suppl 178:79–83.
Sheehan NJ. Dysphagia and other manifestations of esophageal involvement in the musculoskeletal diseases. Rheumatology. 2008;47:746–52.
Medrano M. Dysphagia in a patient with rheumatoid arthritis and iron deficiency anaemia. MedGenMed. 2002;4:10.
Pehlivanov N, Liu J, Mittal RK. Sustained esophageal contraction: a motor correlate of heartburn symptom. Am J Physiol Gastrointest Liver Physiol. 2001;281:G743–51.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer India
About this chapter
Cite this chapter
Singh, S. (2015). Medical Management of Swallowing Disorders. In: Mankekar, G. (eds) Swallowing – Physiology, Disorders, Diagnosis and Therapy. Springer, New Delhi. https://doi.org/10.1007/978-81-322-2419-8_8
Download citation
DOI: https://doi.org/10.1007/978-81-322-2419-8_8
Publisher Name: Springer, New Delhi
Print ISBN: 978-81-322-2418-1
Online ISBN: 978-81-322-2419-8
eBook Packages: MedicineMedicine (R0)